CoChat

Glucocorticoids

Adcock, Ian M., Mumby, Sharon · 2016 · Handbook of experimental pharmacology

The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.

Abstract

The most effective anti-inflammatory drugs used to treat patients with airways disease are topical glucocorticosteroids (GCs). These act on virtually all cells within the airway to suppress airway inflammation or prevent the recruitment of inflammatory cells into the airway. They also have profound effects on airway structural cells to reverse the effects of disease on their function. Glucorticosteroids act via specific receptors-the glucocorticosteroid receptor (GR)-which are a member of the nuclear receptor family. As such, many of the important actions of GCs are to modulate gene transcription through a number of distinct and complementary mechanisms. Targets genes include most inflammatory mediators such as chemokines, cytokines, growth factors and their receptors. GCs delivered by the inhaled route are very effective for most patients and have few systemic side effects. However, in some patients, even high doses of topical or even systemic GCs fail to control their disease. A number of mechanisms relating to inflammation have been reported to be responsible for the failure of these patients to respond correctly to GCs and these provide insight into GC actions within the airways. In these patients, the side-effect profile of GCs prevent continued use of high doses and new drugs are needed for these patients. Targeting the defective pathways associated with GC function in these patients may also reactivate GC responsiveness.

Overview

Integrity signals

Registry

Crossref · 10.1007/164_2016_98

Cites

137 of 137 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 137 references

Research works printed but not linked: 11

  1. Adcock IM, Caramori G, Chung KF (2008b) New targets for drug development in asthma. Lancet 372(9643):1073–1087 · DOI · Paper page
  2. Brompton Hospital/Medical Research Council Collaborative Trial (1974) Double-blind trial comparing two dosage schedules of beclomethasone dipropionate aerosol in the treatment of chronic bronchial asthma. Lancet 2(7876):303–307
  3. Choy DF, Hart KM, Borthwick LA, Shikotra A, Nagarkar DR, Siddiqui S, Jia G, Ohri CM, Doran E, Vannella KM, Butler CA, Hargadon B, Sciurba JC, Gieseck RL, Thompson RW, White S, Abbas AR, Jackman J, Wu LC, Egen JG, Heaney LG, Ramalingam TR, Arron JR, Wynn TA, Bradding P (2015) TH2 and TH17 inflammatory pathways are reciprocally regulated in asthma. Sci Transl Med 7(301):301
  4. Clark TJ (1982) Safety of inhaled corticosteroids. Eur J Respir Dis Suppl 122:235–242
  5. Global Initiative for Asthma (GINA) Global strategy for asthma management and prevention. NHLBI/WHO Workshop report 2002. NHI Publication 02-3659. http://www.ginasthma.com. Accessed 11 May 2015
  6. Hochhaus G, Druzgala P, Hochhaus R, Huang MJ, Bodor N (1991) Glucocorticoid activity and structure activity relationships in a series of some novel 17 alpha-ether-substituted steroids: influence of 17 alpha-substituents. Drug Des Discov 8(2):117–125
  7. Hua G, Ganti KP, Chambon P (2016a) Glucocorticoid-induced tethered transrepression requires SUMOylation of GR and formation of a SUMO-SMRT/NCoR1-HDAC3 repressing complex. Proc Natl Acad Sci U S A 113(5):E635–E643
  8. Hua G, Paulen L, Chambon P (2016b) GR SUMOylation and formation of an SUMO-SMRT/NCoR1-HDAC3 repressing complex is mandatory for GC-induced IR nGRE-mediated transrepression. Proc Natl Acad Sci U S A 113(5):E626–E634
  9. Kupczyk M, Wenzel S (2012) U.S. and. European severe asthma cohorts: what can they teach us about severe asthma? J Intern Med 272(2):121–132
  10. Nannini LJ, Poole P, Milan SJ, Holmes R, Normansell R (2013) Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 11:CD003794
  11. Yang IA, Clarke MS, Sim EH, Fong KM (2012) Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 7:CD002991

Cited by

Items 101–131 of 131

Metadata

Authors
Adcock, I. M., & Mumby, S.
Affiliations
Imperial College London (GB)
Corresponding author
Adcock, Ian M.
Venue
Handbook of experimental pharmacology
Published
2016
Volume
237
Pages
171-196
ISSN
  • 0171-2004 (ISSN-L)
  • 1865-0325
OpenAlex
W4211105534
Cited by
131
References
137
Citations by year
2026: 8 · 2025: 13 · 2024: 19 · 2023: 15 · 2022: 14 · 2021: 30 · 2020: 15 · 2019: 13 · 2018: 1 · 2017: 1 · 2016: 1
FWCI
21.63
Type
book chapter
Language
en
Open access
closed
Locations
  • Handbook of experimental pharmacology (publishedVersion)
  • PubMed (publishedVersion)
  • Spiral (Imperial College London) (submittedVersion)
Funders
  • Wellcome Trust
  • British Heart Foundation (PG/14/27/30679)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords
glucocorticoids, topical glucocorticosteroids, airway inflammation, glucocorticoid receptor, nuclear receptors, gene transcription, chemokines, cytokines, inhaled corticosteroids, glucocorticoid resistance, glucocorticoid adverse effects, anti-inflammatory agents
MeSH terms
Animals, Asthma, Glucocorticoids, Humans, Receptors, Glucocorticoid, Oxidative Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.